

MANAGEMENT TEAM

Christopher J. Moreau
Chief Executive Officer

Dr. Christopher Bryan, PhD
Vice President Research & Operations

James Kinley, CPA, CA
Chief Financial Officer & Director

Dr. Ahmed Khalil, MD, PhD
Medical Director

MEDICAL & SCIENTIFIC ADVISORS

BOARD OF DIRECTORS

Harry J. F. Bloomfield, KC

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD, FAMN, FRCP

Dr. Mark Williams, PhD

U.S. Ambassador (Rtd)
Howard Gutman

STOCK INFORMATION

(March 13, 2023)

Shares O/S: 9.667 Million

Market Cap: C\$ 5.2 Million

Recent Price: C\$.54

TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGWO

INVESTOR INQUIRIES

Christopher J. Moreau, CEO

604.398.4175

chris@algernonpharmaceuticals.com

HEAD OFFICE

Algernon Pharmaceuticals Inc.

Suite 400 - 601 West Broadway

Vancouver, BC, Canada, V5Z 4C2

CORPORATE PRESENTATION

COMPANY OVERVIEW

Algernon is a Canadian clinical stage drug development and repurposing company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for chronic cough and idiopathic pulmonary fibrosis ("IPF"), chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury (TBI). Two of Algernon's lead drugs are based on drug repurposing and the third compound is a naturally occurring psychedelic drug.

Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe.

We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team and a globally recognized medical and scientific advisory board.

ALGERNON PHARMACEUTICALS CLINICAL PIPELINE

CANDIDATE	INDICATION	DEVELOPMENT STAGES				
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY REVIEW
Inflammatory Disorders						
IFENPRODIL	Chronic Cough & Idiopathic Pulmonary Fibrosis				Phase 2a Pilot Study Complete Phase 2b Cough Study Planned - Q3, 2023	
REPIRINAST	Chronic Kidney Disease			Began cGMP Manufacturing - Q1, 2022 Phase 1 Planned - Q3, 2023		
Cerebrovascular Disorders						
DMT N, N-DIMETHYLTRYPTAMINE	Stroke and Traumatic Brain Injury			Began Phase 1 - Q1, 2023		

ALGERNON'S LEAD CLINICAL RESEARCH PROGRAMS

CHRONIC COUGH AND IDIOPATHIC PULMONARY FIBROSIS (IPF)

Algernon recently announced positive data showing that it met the co-primary endpoint in its Phase 2a proof of concept study evaluating NP-120 ("Ifenprodil") for the potential treatment of IPF and chronic cough. In the study, 65% of patients had stable or improved forced vital capacity ("FVC") over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%. FVC is the amount of air that can be forcibly exhaled from one's lungs after taking the deepest breath possible.

For the chronic cough part of the study's primary endpoint:

- The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks and 39.5% at 12 weeks, both with significance compared to baseline
- The geometric mean awake cough counts were reduced by 30.2% at 4 weeks and 37.4% at 12 weeks with statistical significance compared to baseline

* The IPF market is expected to reach a value of USD \$3.2 B by 2025.

* The chronic cough market is expected to reach a value of USD \$9.8 B by 2027.

RECENT DEVELOPMENTS

MARCH 21, 2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

MARCH 02, 2023

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

FEBRUARY 28, 2023

Algernon Pharmaceuticals Announces 4 for 1 Forward Share

FEBRUARY 21, 2023

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

FEBRUARY 16, 2023

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

JANUARY 17, 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

JANUARY 11, 2023

Algernon Pharmaceuticals Appoints Dr. Peter Dicipinigaitis to Chronic Cough Advisory Board

JANUARY 09, 2023

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

STROKE AND TRAUMATIC BRAIN INJURY (TBI)

Algernon has established a new subsidiary called Algernon NeuroScience to advance its clinical research program for the treatment of stroke and traumatic brain injury (TBI) focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin).

Algernon is conducting a Phase 1 clinical study of an intravenous formulation of DMT in the Netherlands. The trial is taking place at the Centre for Human Drug Research (“CHDR”) in Leiden.

** The global stroke treatment market is expected to reach a value of USD \$15 B by the year 2027.*

** The global TBI treatment market is expected to reach a value of USD \$4.5 B by 2026*

CHRONIC KIDNEY DISEASE (CKD)

Algernon’s lead compound for the treatment and management of chronic kidney disease (“CKD”) is Repirinast, an orally administered small molecule. Repirinast acts on mast cells and inhibits the release of chemical mediators by IgE-related antigen antibody interactions. Repirinast, in a unilateral ureteral obstruction mouse model of kidney fibrosis reduced fibrosis by 50% with statistical significance. Algernon has begun manufacturing a cGMP supply of the drug and is planning a phase 1 study in Q2, 2023.

** The global CKD drug market is expected to reach value of USD \$15.8 B by the end of 2024.*

ALGERNON CEO INTERVIEWS

Please visit the media section on the website for a more fulsome list of interviews.



Christopher J. Moreau
Chief Executive Officer

- **THE DALES REPORT - WHY PSYCHEDELIC TREATMENTS WILL BENEFIT INVESTORS AND HEALTHCARE**
- **RADIUS RESEARCH INTERVIEW – ALGERNON NEUROSCIENCE INITIATES TBI RESEARCH PROGRAM WITH DMT**
- **PROACTIVE INVESTORS CEO INTERVIEW – ALGERNON NEUROSCIENCE COMPLETES FIRST DOSING IN PHASE 1 CLINICAL STUDY OF DMT**
- **RADIUS RESEARCH INTERVIEW – ALGERNON PHARMACEUTICALS (AGN) CEO CHRISTOPHER J. MOREAU – IFENDPRODIL PROGRAM UPDATE TARGETING CHRONIC COUGH**

ALGERNON IN THE NEWS

- **SR TIMES – “DRUG COULD POSSIBLY BOTH REDUCE ACUTE DAMAGE OF THE STROKE” – HOW DMT COULD BE THE FUTURE OF STROKE TREATMENT**
- **BENZINGA – A PSYCHEDELIC PROGRAM FOR TREATMENT OF STROKE: NEW CLINICAL TRIAL BEGINS DOSING**
- **MICRODOSE: MICRODOSING DMT TO TREAT STOKES: NOT AS TRIPPY AS IT SOUNDS**
- **BENZINGA – PSYCHEDELIC SUBSIDIARIES NEWS: BLACKHAWK SPINS OUT THREE COMPANIES, ALGERNON CREATES A NEW ONE**